Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18660634 | 0.88 | CHRM1 (0.32) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL24023415 | 0.83 | FOLH1 (0.34) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| Hydrochloric Acid SCHEMBL18757101 | 0.83 | FOLH1 (0.33) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL18660439 | 0.83 | FOLH1 (0.33) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL25866277 | 0.83 | — | — | |
| SCHEMBL15413215 | 0.79 | FOLH1 (0.36) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL20510285 | 0.79 | FOLH1 (0.38) | FOLH1CHRM1TBXA2RADRA1A | |
| SCHEMBL18631724 | 0.79 | L3MBTL1 (0.32) | FOLH1CHRM1TBXA2RADRA1A | |
| SCHEMBL10156632 | 0.78 | ALDH1A1 (0.37) | FOLH1HTR7CHRM1TBXA2RADRA1A | |
| SCHEMBL15413216 | 0.78 | FOLH1 (0.38) | FOLH1HTR7CHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281083-B1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | BRII BIOSCIENCES INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250381209-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | BRII BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12370208-B2 | Adenosine derivative and pharmaceutical composition comprising the same | BRII BIOSCIENCES, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12257264-B2 | Combination therapy for HIV with adenosine derivative and capsid inhibitors | BRII BIOSCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240180949-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | BRII BIOSCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| US-11890297-B2 | Combination therapy for HIV with adenosine derivative and capsid inhibitors | BRII BIOSCIENCES, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4281083-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | Brii Biosciences, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220288098-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220249532-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | BRII BIOSCIENCES, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-4003369-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Brii Biosciences, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| WO-2021021717-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257264-B2 | Combination therapy for HIV with adenosine derivative and capsid inhibitors | ADAR, ADA, NSUN2 | FOLH1 1435/4885HTR7 2911/4885CHRM1 3956/4885 |
| US-20230226093-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | FOLH1 1054/4885HTR7 1159/4885CHRM1 3521/4885 |
| US-20220249532-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | ADAR, ADA, NSUN2 | FOLH1 1435/4885HTR7 2911/4885CHRM1 3956/4885 |
| US-20250381209-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | ADAR, ADA, NSUN2 | FOLH1 1435/4885HTR7 2911/4885CHRM1 3956/4885 |
| US-12370208-B2 | Adenosine derivative and pharmaceutical composition comprising the same | ADAR, ADA, ADORA2A | FOLH1 1054/4885HTR7 1159/4885CHRM1 3521/4885 |
| US-20240180949-A1 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | ADAR, ADA, NSUN2 | FOLH1 1435/4885HTR7 2911/4885CHRM1 3956/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | FOLH1 403/4885HTR7 2828/4885CHRM1 631/4885 |
| US-11890297-B2 | Combination therapy for HIV with adenosine derivative and capsid inhibitors | ADAR, ADA, NSUN2 | FOLH1 1435/4885HTR7 2911/4885CHRM1 3956/4885 |
| US-20220288098-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | FOLH1 1054/4885HTR7 1159/4885CHRM1 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.